论文部分内容阅读
目的探讨胺碘酮短时期治疗急性心力衰竭合并快速心律失常患者的临床效果。方法选取2013年2月至2016年8月凤城市中心医院收治的145例急性心力衰竭合并快速心律失常患者,将其分为观察组(72例)和对照组(73例)。对照组患者采用艾司洛尔治疗,观察组患者采用胺碘酮治疗,比较两组患者的治疗效果。结果治疗后,两组患者的N-末端脑钠肽前体(NT-proBNP)水平和心率(HR)均显著降低,且观察组患者的NT-proBNP水平、HR均明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率差异无统计学意义(P>0.05)。结论使用胺碘酮短时期治疗急性心力衰竭合并快速心律失常临床效果显著,且安全性较高。
Objective To investigate the clinical effect of amiodarone for short-term treatment of patients with acute heart failure complicated with tachyarrhythmia. Methods A total of 145 patients with acute heart failure complicated with tachyarrhythmia admitted from Fengcheng Central Hospital from February 2013 to August 2016 were divided into observation group (72 cases) and control group (73 cases). Control group patients with esmolol treatment, observation group patients treated with amiodarone, the treatment effect of two groups were compared. Results After treatment, the levels of NT-proBNP and heart rate (HR) were significantly decreased in both groups, and the NT-proBNP level and HR in the observation group were significantly lower than those in the control group (P <0.05). The total effective rate of treatment group was significantly higher than that of control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups P> 0.05). Conclusions Short-term use of amiodarone in the treatment of acute heart failure with tachyarrhythmia has a significant clinical effect and is safe.